What’s going on with the Novacyt (NCYT) share price?

After months of decline, the Novacyt (NCYT) share price started rising last month. Is this a sign to buy? Zaven Boyrazian takes a closer look.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

It’s been a rough almost-half-year for the Novacyt (LSE:NCYT) share price. Despite surging throughout 2020, and the early part of 2021, the stock crashed in April and has continued trending downward. But just last month, it popped back up again and managed to shift the 12-month performance to around +24%.

It’s still nowhere close to where it was at the start of the year. But could the recent jump be an indicator that the firm’s woes are over? And should I be considering this business for my portfolio?

NCYT share price jumps on earnings

Last month, Novacyt published its six-month performance report. And at first glance, it was pretty impressive. The diagnostics specialist brought in £94.7m in revenue. That’s about 50% higher than in 2020, so I can see why the market reacted positively to the news. However, on closer inspection, this trading update may not be as fantastic as it seems.

Should you invest £1,000 in Novacyt S.a. right now?

When investing expert Mark Rogers has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for nearly a decade has provided thousands of paying members with top stock recommendations from the UK and US markets. And right now, Mark thinks there are 6 standout stocks that investors should consider buying. Want to see if Novacyt S.a. made the list?

See the 6 stocks

I’ve previously explored what triggered the NCYT share price to crash in April. But as a quick reminder, the firm’s biggest source of income is a single contract with the Department of Health and Social Care (DHSC). Under this agreement, Novacyt supplies the NHS with Covid-19 testing kits. And it has proven to be a very lucrative deal, which was behind the stock’s surge last year.

Unfortunately, this contract was not extended as originally anticipated. And overnight, the vast majority of the firm’s revenue stream evaporated. Of the £94.7m reported as revenue this year, £40.8m originates from the DHSC and is currently in dispute. In other words, it remains unpaid.

The Novacyt NCYT share price has its risks

It’s not all bad news

A more honest picture of the group’s performance can be seen by its non-DHSC income. This came in at around £53.9m, up around 20% versus last year. That’s still a good level of growth, and it seems it will continue throughout the rest of 2021. Why? Because Novacyt has managed to acquire several new contracts.

Firstly, its subsidiary, Primerdesign, has signed a new deal with the DHSC worth £4.7m, which runs until March 2022. The management team has also negotiated an extension with UNICEF to keep supplying Covid-19 tests until July 2022. Meanwhile, testing in the private sector continues to see high demand for Novacyt products, especially its latest generation of testing kits that can detect the key variants of Covid-19.

Consequently, management has posted a revenue forecast for the year of £100m, excluding income from its disputed DHSC contract. And compared to non-DHSC income last year, this is a notable increase. If the company can continue to grow moving forward, the NCYT share price could recover over the long term.

The bottom line

It’s encouraging to see the group’s revenue stream start to recover the recently-lost income. And, more importantly, diversify its revenue sources. However, one glaring issue I spotted in this latest update is the lack of information surrounding how the business will thrive in a post-pandemic world.

Currently, almost all sales are generated by Covid-related products. But the demand for these will naturally start declining as the pandemic comes to an end. Therefore, until management can answer how it plans to continue growing over the long term, I’ll be keeping this business on my watchlist.

5 Shares for the Future of Energy

Investors who don’t own energy shares need to see this now.

Because Mark Rogers — The Motley Fool UK’s Director of Investing — sees 2 key reasons why energy is set to soar.

While sanctions slam Russian supplies, nations are also racing to achieve net zero emissions, he says. Mark believes 5 companies in particular are poised for spectacular profits.

Open this new report5 Shares for the Future of Energy — and discover:

  • Britain’s Energy Fort Knox, now controlling 30% of UK energy storage
  • How to potentially get paid by the weather
  • Electric Vehicles’ secret backdoor opportunity
  • One dead simple stock for the new nuclear boom

Click the button below to find out how you can get your hands on the full report now, and as a thank you for your interest, we’ll send you one of the five picks — absolutely free!

Grab your FREE Energy recommendation now

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Zaven Boyrazian has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Prediction: these FTSE 100 stocks could be among 2025’s big winners

Picking the coming year's FTSE 100 winners isn't an easy task, but we're all thinking about it at this time…

Read more »

Investing Articles

This UK dividend share is currently yielding 8.1%!

Our writer’s been looking at a FTSE 250 dividend share that -- due to its impressive 8%+ yield -- is…

Read more »

Investing Articles

If an investor put £10,000 in Aviva shares, how much income would they get?

Aviva shares have had a solid run, and the FTSE 100 insurer has paid investors bags of dividends too. How…

Read more »

Investing Articles

Here’s why I’m still holding out for a Rolls-Royce share price dip

The Rolls-Royce share price shows no sign of falling yet, but I'm still hoping it's one I can buy on…

Read more »

Investing Articles

Greggs shares became 23% cheaper this week! Is it time for me to take advantage?

On the day the baker released its latest trading update, the price of Greggs shares tanked 15.8%. But could this…

Read more »

Investing Articles

Down 33% in 2024 — can the UK’s 2 worst blue-chips smash the stock market this year?

Harvey Jones takes a look at the two worst-performing shares on the FTSE 100 over the last 12 months. Could…

Read more »

Concept of two young professional men looking at a screen in a technological data centre
Investing Articles

Are National Grid shares all they’re cracked up to be?

Investors seem to love National Grid shares but Harvey Jones wonders if they’re making a clear-headed assessment of the risks…

Read more »

Investing For Beginners

Here’s what the crazy moves in the bond market could mean for UK shares

Jon Smith explains what rising UK Government bond yields signify for investors and talks about what could happen for UK…

Read more »